EGFR Mutant Lung Cancer
| Autor: | William Pao, Yixuan Gong |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
biology
business.industry medicine.medical_treatment Drug resistance medicine.disease respiratory tract diseases Targeted therapy Gefitinib medicine Cancer research biology.protein Adenocarcinoma Anaplastic lymphoma kinase Epidermal growth factor receptor Lung cancer Erlotinib Hydrochloride business medicine.drug |
| Zdroj: | Therapeutic Kinase Inhibitors ISBN: 9783642282959 |
| Popis: | Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases. Lung adenocarcinoma subsets now can be defined by specific ‘driver’ mutations in genes encoding components of the EGFR signaling pathway. Importantly, these mutations have implications regarding targeted therapy. Here, we focus on EGFR mutant NSCLC—a prime example of a clinically relevant molecular subset of lung cancer, with defined mechanisms of drug sensitivity, primary drug resistance, and acquired resistance to EGFR tyrosine kinase inhibitors. Efforts are now being made to overcome mechanisms of acquired resistance. These findings illustrate how knowledge about the genetic drivers of tumors can lead to rational targeted therapy for individual patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|